Standard Biotools provides update on sale of mass cytometry business

LAB•2026-09-30

Standard BioTools terminated its previously announced agreement to sell its mass cytometry business to Multiplex Bio and entered a definitive agreement to sell it to Element Biosystems for $5.5 million in cash payable.

1. Sale agreement changed

Standard BioTools terminated its previously announced agreement to sell its mass cytometry business to Multiplex Bio. The company entered a definitive agreement to sell the business to Element Biosystems for $5.5 million in cash payable.

Standard Biotools provides update on sale of mass cytometry business

1. Sale agreement changed

Related News

CTO Realty Growth closes $1.0 billion unsecured credit agreement

Par Pacific EVP Jerry Stumbo files initial beneficial ownership statement

Inogen announces divestiture of U.S. oxygen rental business to Rotech

Adicet Bio grants new-hire stock options for 725 shares at $7.14 each under inducement plan

BioCardia CEO Peter Altman acquires $1,030 in common shares